Danaher Guides 3Q Core Revenue Growth of 2%-3%, Signaling Steady Demand
DHR sits 25% above its 52-week low of $160.93.
Summary
Danaher provided 3Q adjusted core revenue growth guidance of 2%-3%, a concrete forward-looking metric that gives traders a clear baseline for the quarter. The company also stated that continued end-market recovery and traction from growth initiatives support its expectation to exit 2026 at a mid-single-digit core revenue growth rate. This follows a busy period of financing and M&A, including the completed Masimo acquisition and a recent bolt-on by Leica Biosystems. The guidance suggests organic demand is holding up, which matters for a $142B life sciences giant where growth expectations drive valuation. No specific earnings date is set, but the next quarterly report will be the key check against this forecast.
At the time of this announcement, DHR was trading at $201.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $142.3B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.